Donate For Public and Patients Store Search

S027 - Best Evidence Based Opportunities for Cost-effective Skin Care

Saturday, March 2; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Assess cost effective care of various skin diseases and conditions including onychomycosis, leg ulcers, and acne among others
  • Examine evidence that drives decision making for skin disease such as hair loss, pruritus and lupus among others


This session will examine the evidence and provide an evidenced based discussion about best cost effective practices to care for patients with lupus, acne, pruritus, leg ulcers, onychomycosis, as well as discuss the cost benefit of inpatient dermatology and rebate programs


  • Adamson, Adewole Shomari, MD, MPP: no financial relationships exist with commercial interests.
  • Kia, Kevin, MD: no financial relationships exist with commercial interests.
  • Kirsner, Robert S., MD, PhD: AbbVie – C(Grants/Research Funding); Kerecis Limited – A(H); Molynecke – A(H); National Healing Corp – A(H); Pfizer Inc. – A(H);
  • Maderal, Andrea, MD: no financial relationships exist with commercial interests.
  • Mauskar, Melissa Muszynski, MD: no financial relationships exist with commercial interests.
  • Tosti, Antonella, MD: Aclaris Therapeutics, Inc. – A(H); Anacor Pharmaceuticals, Inc. – A(H); DS Laboratories – C(Fees); Fotofinder – C(EQ); Incyte Corporation – C(H); Kurt Wolff GmbH & Co. KG – A(H); Kythera – A(H); Meiji Seika Pharma Co., Ltd – A(H); MSD – SP(H); Novartis – A(H); PharmaDerm – Speaker/Faculty Education(H); Pierre Fabre Dermatologie – C(H); Polichem SA – A(H); Procter & Gamble Company – A(H); Springer Science & Business Media – O(IP); Taylor & Francis – O(IP); topica – C(Fees); Valeant Pharmaceuticals International – C(Fees); Viamet Pharmaceuticals, Inc – A(H);
  • Yosipovitch, Gil, MD: Galderma Laboratories, L.P. – A(H); Kiniksa Pharmaceuticals, Ltd. – I(Grants/Research Funding); Menlo Therapeutics – A(H), I(Grants/Research Funding); Novartis – C(H); OPKO Health, Inc – C(H); Pfizer Inc. – A(H), I(Grants/Research Funding); Sanofi/Regeneron – A(H); Sienna Biopharmaceuticals – A(H); Sun Pharmaceutical Industries Ltd. – I(Grants/Research Funding); Trevi Therapeutics – A(H);
Saturday, March 2
1:00 PM
/ Introduction
1:05 PM
Dr. Kia / Oral vs. New Topical Care for Acne
1:25 PM
Dr. Adamson / Rebate Care Programs: Are they Cost Effective Care?
1:45 PM
Dr. Tosti / Cost Effective Management of Patterned Hair Loss
2:05 PM
Dr. Yosipovitch / Cost Effective Evaluation and Treatment of Pruritus
2:25 PM
Dr. Kirsner / Cost Effective Care of Leg Ulcers
2:45 PM
Dr. Mauskar / Evidenced Based Cost Effective Inpatient Dermatology
3:05 PM
Dr. Maderal / Best Cost Effective Care of Lupus
3:25 PM
Dr. Kia / Oral vs. New Topical Care for Onychomycosis
3:45 PM
Dr. Kia / Summary and Conclusion
Event Details
  • Date
    Saturday, March 2
  • Time
    1:00 PM - 4:00 PM
  • Location
    Room 102B
  • CME Credits
  • Type
  • Robert S. Kirsner, MD, PhD, FAAD
  • Kevin Kia, MD, FAAD
  • Adewole Shomari Adamson, MD, MPP, FAAD
  • Andrea Maderal, MD, FAAD
  • Antonella Tosti, MD - Handout
  • Gil Yosipovitch, MD
  • Melissa Muszynski Mauskar, MD, FAAD